The NIH Chemical Countermeasures Research Program (CCRP) supports the discovery and early development of medical countermeasures (MCMs) to advance the nation's medical and public health preparedness for, response to, and recovery from high consequence chemical disasters and emergencies. The civilian chemical threat spectrum includes chemical warfare agents, toxic industrial chemicals, pesticides, pharmaceutical-based agents, and others that have been identified by the U.S. government as chemicals of concern (CoCs).
The CCRP is a trans-NIH initiative established by NIAID in 2006 and involves partnerships with multiple NIH institutes including NEI, NIAMS, NICHD, NIEHS, NIDA, and NINDS. Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents, and attacks, and emerging infectious diseases. BARDA provides funding for potential medical countermeasures to enable drug development and regulatory processes through the Food and Drug Administration (FDA). In this webinar, we will have presentations from and conversations with David Yeung, PhD, Acting Chief, Biodefense Research Countermeasures Branch and Director of the NIH Chemical Countermeasures Research Program (CCRP), and Devon Andres, PhD, DABT, Biologist and Project Officer, Chemical Medical Countermeasures, Division of Chemical, Biological, Radiological and Nuclear (CBRN) Countermeasures, BARDA. The speakers will cover topics such as the mission of their agencies, program priorities, funding opportunities, and keys to successful funding applications.